On August 24th, Semiconductors International (06969) released its financial report for the first half of 2022. The company reported a revenue of RMB 5.65 billion and an adjusted net profit of RMB 1.44 billion.
In the first half of 2022, Chen Zhiping, Chairman of the Board of Directors of Sumitomo International, expressed the company's commitment to long-term thinking in the face of an ever-changing and challenging external environment. The company will continue to invest in the future and adhere to its long-term philosophy. Scientific and technological innovation is the driving force of Sumitomo's development, and only by adhering to innovation can the company build long-term competitiveness and create long-term value for the country, customers, employees, and shareholders.
The US market helps clients become number one, while the Chinese market actively supports regulation.
The financial report reveals that from January to June 2022, Simore's operating income was 5.65 billion and adjusted net profit was 1.44 billion.
Behind the stable revenue is SMOORE's active layout in the electronic atomization market and the diversity of its income distribution. According to data, in the first half of the year, SMOORE's enterprise customer business (ODM) and retail customer business (APV) grew rapidly in Europe. In terms of revenue for the first half of the year, the proportion of income from countries and regions outside of China and the United States was 39%, an increase of 16 percentage points compared to the same period last year, which was 23%.
In the US market, Smoore, with its technological and manufacturing advantages, has become a leading manufacturer of ENDS (electronic nicotine delivery systems) that assists many customers to pass PMTA (premarket tobacco product application). Additionally, Smoore has helped its customers gain market share by offering reasonable prices. It is expected that the company will maintain stable and healthy orders throughout the second half of the year.
In the Chinese market, Smoore supports regulatory policies. The current planning and regulation by the National Tobacco Monopoly Administration marks a new starting point for industry development in accordance with regulations. Smoore strictly adheres to regulatory requirements and actively applies for tobacco monopoly production licenses. Currently, three subsidiaries have already been granted production licenses. Smoore will continue to strengthen research and development of products that meet national standards to meet regulatory requirements and provide consumers with a better experience. At the same time, it will ensure the delivery of products that meet national standards from the manufacturing end.
Research and development investment has increased significantly by 156%, as the company continues to focus on internal innovation to build its core competitiveness.
Chen Zhiping stated that on the path of creating a globally leading atomization technology platform, it is impossible to have a completely smooth journey. We will continue to believe in the promising future of atomization technology, persist in invention and innovation, and remain committed to a long-term strategy.
As a result, SiMoEr has been increasing their research and development investment according to their planned schedule. They are focusing particularly on areas such as basic research, new materials research, and atomization medical treatment in order to improve their talent density, establish a global research and development system, and build their core competitiveness. In the first half of the year, their research and development expense was 604 million yuan, which is a 156% increase compared to the same period last year.
During the first half of the year, 14 basic research institutes were put into operation globally, with several important scientists and hundreds of masters and doctoral students from renowned universities joining the company. As of June 30th, there were 1,472 R&D experts at SMIC, accounting for over 40% of the total R&D personnel.
Top talent joining has enabled Semler to further cultivate core technology and build a core patent barrier. Currently, there are 4,337 patent applications globally, with 929 newly added applications in the first half of this year. In April of this year, "Semler's launch of a 337 rights protection investigation in the US" was consecutively selected as one of the top ten intellectual property events in Guangdong Province and Shenzhen City in 2021.
Medical atomization products smoothly enter domestic approval channel.
In the field of medical nebulization, Simoer has established a wholly-owned subsidiary in the United States to focus on the research and development of respiratory drug products, providing relief for patients with asthma and chronic obstructive pulmonary disease. Currently, they have reached an agreement with one of the world's largest pharmaceutical manufacturing companies to develop two nebulized drugs. If the products are approved smoothly, they are expected to be launched in the next few years.
In addition, Simoer's first domestic research and development of a nebulizer device is currently going through the approval process in China.
In the first half of the year, exports generated 3.955 billion yuan in foreign exchange earnings. The four major directions for reducing carbon emissions were announced as a priority.
As a "dream chaser with love", Si Moer continuously responds to public expectations and practices corporate social responsibility through concrete actions.
In the first half of the year, SMIC generated 3.955 billion USD in foreign exchange earnings by exporting to overseas markets. To address the challenging situation of over 10 million university graduates in 2022, SMIC has established deep school-enterprise cooperation relationships with 15 colleges and universities, cultivating and supplying over 1,000 skilled workers to the industry. Additionally, SMIC is actively implementing talent management programs, such as "SMIC model talent" and "SMIC skilled talent," targeting graduates in 2022 and 2023.
In addition, as the first vaporization technology company to list a carbon neutrality schedule, Simoer has released its carbon reduction targets and plans to achieve carbon neutrality within scopes 1 and 2 by 2050. Data shows that in 2021, Simoer has achieved a year-on-year decrease in greenhouse gas emissions density of about 16% and a year-on-year reduction in water consumption density of about 9.4%.
During the first half of the year, semiconductor company SMIC was able to maintain its A-grade rating in ESG evaluations published by MSCI, the world's largest index provider. Additionally, SMIC was awarded five major prizes, including the award for corporate governance (ESG), in the 2022 Asia Management Team selection.
This article includes excerpts or reprints of information from third-party sources. Copyright belongs to the original media and authors. If there is any infringement, please contact us for deletion. Any organization or individual who wishes to reprint must contact the author. Please do not directly repost.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
